NLS drug-2

The first patient has been dosed in a Phase I trial of TILT Biotherapeutics’ oncolytic adenovirus TILT-123. The multi-centre open-label, phase I, dose-escalation trial will evaluate igrelimogene litadenorepvec (TILT-123) in combination with avelumab in squamous cell carcinoma of head and neck (SCCHN), and melanoma in patients with advanced solid tumors refractory to, or progressing after, […]

Cantargia has announced a successful safety review of the ten non-squamous non-small cell lung cancer (NSCLC) patients treated with its lead asset nadunolimab (CAN04) and carboplatin/pemetrexed in the phase I/IIa CANFOUR trial. Enrollment to this trial has now ended; continued development of nadunolimab in NSCLC will further focus on patient subgroups by implementation of a […]

A second planned interim analysis has been conducted of the ongoing clinical phase 1b study with the company’s vaccine candidate ALZ-101 against Alzheimer’s disease. The analysis shows positive data with continued good safety and tolerability as well as a clear immunological response, that is, that specific antibodies have been formed, states the company. Based on […]

Gedea Biotech has announces that the treatment of the first patients with its lead product, pHyph, a vaginal tablet for topical treatment, has begun. The open-labelled study is designed to confirm the safety and efficacy of pHyph in treating adult women with confirmed Vulvo Vaginal Candidiasis (VVC) and in restoring a beneficial vaginal microbiome to […]

Alligator Bioscience and Amphera have announce the successful dosing of the last patient in the REACTIVE-2 Phase 1 trial evaluating mitazalimab in combination with MesoPher in patients with metastatic pancreatic cancer. The open-label, single-center Phase 1 dose finding study is assessing the safety and efficacy of Alligator’s lead asset mitazalimab, in combination with Amphera’s cancer […]

BioInvent International has announced that a fourth complete response has been observed in the 100 mg dose expansion cohort in the IV arm of the Phase 1/2 trial of its lead drug candidate BI-1206, the novel anti-FcgRIIB antibody, in combination with rituximab in non-Hodgkin’s lymphoma (NHL). The study is recruiting patients with NHL who have […]